Curcumin Modulates the Radiosensitivity of Colorectal Cancer Cells by Suppressing Constitutive and Inducible NF-κB Activity

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 2, 2009, Pages 534-542

  Sandur, Santosh K ^a   Deorukhkar, Amit ^a   Pandey, Manoj K ^a   Pabón, Ana María ^a   Shentu, Shujun ^a   Guha, Sushovan ^a   Aggarwal, Bharat B ^a   Krishnan, Sunil ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Colorectal cancer; Curcumin; Nuclear factor B; Radiation; Radiosensitization

Indexed keywords

, INHIBITOR; ACTIVE INGREDIENTS; AKT PHOSPHORYLATION; ANTITUMOR EFFECT; CLONOGENIC SURVIVAL; COLORECTAL CANCER; COLORECTAL CANCER CELL; CONSTITUTIVELY ACTIVES; CURCUMIN; CYCLIND1; CYCLOOXYGENASE 2; INTEGRAL PART; KINASE ACTIVITY; NUCLEAR FACTORS; PATHOLOGIC RESPONSE; POSTIRRADIATION; RADIATION THERAPY; RADIATION-INDUCED; RADIORESISTANCE; RADIOSENSITIZATION; RECTAL CANCER; REGULATED GENES; SIGNALING PATHWAYS; TIME-DEPENDENT;

ACTIVATION ANALYSIS; CELL CULTURE; CELL DEATH; CELL MEMBRANES; GAMMA RAYS; ONCOLOGY; PHOSPHORYLATION; PIGMENTS; RADIOTHERAPY; SIGNALING; TRANSCRIPTION; TRANSCRIPTION FACTORS; TUMORS;

RADIATION EFFECTS;

CURCUMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE B;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIATION DOSE; RADIOSENSITIVITY; RADIOSENSITIZATION;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HT29 CELLS; HUMANS; NEOPLASM PROTEINS; NF-KAPPA B; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RECTAL NEOPLASMS;

EID: 69549084702     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.06.034     Document Type: Article

References (49)

1. Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351 (2004) 1731-1740
2. Rodel C., Martus P., Papadoupolos T., et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23 (2005) 8688-8696
3. Janjan N.A., Abbruzzese J., Pazdur R., et al. Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. Radiother Oncol 51 (1999) 153-160
4. Janjan N.A., Crane C., Feig B.W., et al. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 24 (2001) 107-112
5. Crane C.H., Skibber J.M., Feig B.W., et al. Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma. Cancer 97 (2003) 517-524
6. Bonnen M., Crane C., Vauthey J.N., et al. Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients. Int J Radiat Oncol Biol Phys 60 (2004) 1098-1105
7. Krishnan S., Janjan N.A., Skibber J.M., et al. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 66 (2006) 762-771
8. Rodel C., Liersch T., Hermann R.M., et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 25 (2007) 110-117
9. Mohiuddin M., Winter K., Mitchell E., et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 24 (2006) 650-655
10. Czito B.G., Willett C.G., Bendell J.C., et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: Phase I trial results. J Clin Oncol 24 (2006) 656-662
11. Aggarwal B.B. Nuclear factor-κB: The enemy within. Cancer Cell 6 (2004) 203-208
12. Voboril R., and Weberova-Voborilova J. Constitutive NF-κB activity in colorectal cancer cells: Impact on radiation-induced NF-κB activity, radiosensitivity, and apoptosis. Neoplasma 53 (2006) 518-523
13. Yu L.L., Yu H.G., Yu J.P., et al. Nuclear factor-κB p65 (RelA) transcription factor is constitutively activated in human colorectal carcinoma tissue. World J Gastroenterol 10 (2004) 3255-3260
14. Kojima M., Morisaki T., Sasaki N., et al. Increased nuclear factor-κB activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Res 24 (2004) 675-681
15. Yu H.G., Yu L.L., Yang Y., et al. Increased expression of RelA/nuclear factor-κB protein correlates with colorectal tumorigenesis. Oncology 65 (2003) 37-45
16. Arber N., Hibshoosh H., Moss S.F., et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 110 (1996) 669-674
17. Eberhart C.E., Coffey R.J., Radhika A., et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994) 1183-1188
18. Charalambous M.P., Maihofner C., Bhambra U., et al. Upregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-κB and IκBα in human colorectal cancer epithelial cells. Br J Cancer 88 (2003) 1598-1604
19. Mukogawa T., Koyama F., Tachibana M., et al. Adenovirus-mediated gene transduction of truncated IκBα enhances radiosensitivity in human colon cancer cells. Cancer Sci 94 (2003) 745-750
20. Russo S.M., Tepper J.E., Baldwin Jr. A.S., et al. Enhancement of radiosensitivity by proteasome inhibition:implications for a role of NF-κB. Int J Radiat Oncol Biol Phys 50 (2001) 183-193
21. Wang C.Y., Mayo M.W., and Baldwin Jr. A.S. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB. Science 274 (1996) 784-787
22. Tomita M., Kawakami H., Uchihara J.N., et al. Curcumin (diferuloylmethane) inhibits constitutive active NF-κB, leading to suppression of cell growth of human T-cell leukemia virus type I-infected T-cell lines and primary adult T-cell leukemia cells. Int J Cancer 118 (2006) 765-772
23. Shishodia S., Amin H.M., Lai R., et al. Curcumin (diferuloylmethane) inhibits constitutive NF-κB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 70 (2005) 700-713
24. Siwak D.R., Shishodia S., Aggarwal B.B., et al. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IκB kinase and nuclear factor κB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 104 (2005) 879-890
25. Li L., Aggarwal B.B., Shishodia S., et al. Nuclear factor-κB and IκB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 101 (2004) 2351-2362
26. Wei S.C., Lin Y.S., Tsao P.N., et al. Comparison of the anti-proliferation and apoptosis-induction activities of sulindac, celecoxib, curcumin, and nifedipine in mismatch repair-deficient cell lines. J Formos Med Assoc 103 (2004) 599-606
27. Bharti A.C., Shishodia S., Reuben J.M., et al. Nuclear factor-κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103 (2004) 3175-3184
28. Chan M.M., Fong D., Soprano K.J., et al. Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents. J Cell Physiol 194 (2003) 63-70
29. Mehta K., Pantazis P., McQueen T., et al. Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anticancer Drugs 8 (1997) 470-481
30. Villegas I., Sanchez-Fidalgo S., and Alarcon de la Lastra C. New mechanisms and therapeutic potential of curcumin for colorectal cancer. Mol Nutr Food Res 52 (2008) 1040-1061
31. Kunnumakkara A.B., Diagaradjane P., Guha S., et al. Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-κB-regulated gene products. Clin Cancer Res 14 (2008) 2128-2136
32. Takada Y., Khuri F.R., and Aggarwal B.B. Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-κB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-κB-regulated gene expression and up-regulation of apoptosis. J Biol Chem 279 (2004) 26287-26299
33. Sandur S.K., Ichikawa H., Sethi G., et al. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) suppresses NF-κB activation and NF-κB-regulated gene products through modulation of p65 and IκBα kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. J Biol Chem 281 (2006) 17023-17033
34. Ghosh S., and Karin M. Missing pieces in the NF-κB puzzle. Cell 109 Suppl (2002) S81-S96
35. You M., Ku P.T., Hrdlickova R., et al. ch-IAP1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein. Mol Cell Biol 17 (1997) 7328-7341
36. Chu Z.L., McKinsey T.A., Liu L., et al. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control. Proc Natl Acad Sci U S A 94 (1997) 10057-10062
37. Tamatani M., Che Y.H., Matsuzaki H., et al. Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NF-κB activation in primary hippocampal neurons. J Biol Chem 274 (1999) 8531-8538
38. Catz S.D., and Johnson J.L. Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer. Oncogene 20 (2001) 7342-7351
39. Guttridge D.C., Albanese C., Reuther J.Y., et al. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19 (1999) 5785-5799
40. Yamamoto K., Arakawa T., Ueda N., et al. Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem 270 (1995) 31315-31320
41. Wang C.Y., Cusack Jr. J.C., Liu R., et al. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 5 (1999) 412-417
42. Yamagishi N., Miyakoshi J., and Takebe H. Enhanced radiosensitivity by inhibition of nuclear factor kappa B activation in human malignant glioma cells. Int J Radiat Biol 72 (1997) 157-162
43. Kawamura I., Morishita R., Tsujimoto S., et al. Intravenous injection of oligodeoxynucleotides to the NF-κB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice. Gene Ther 8 (2001) 905-912
44. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
45. Chendil D., Ranga R.S., Meigooni D., et al. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 23 (2004) 1599-1607
46. Li M., Zhang Z., Hill D.L., et al. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3 K/mTOR/ETS2 pathway. Cancer Res 67 (2007) 1988-1996
47. Lao C.D., Ruffin IV M.T., Normolle D., et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6 (2006) 10
48. Cruz-Correa M., Shoskes D.A., Sanchez P., et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 4 (2006) 1035-1038
49. Garcea G., Berry D.P., Jones D.J., et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14 (2005) 120-125